Enzalutamide has demonstrated impressive efficacy in men with metastatic CRPC, moving swiftly from a phase I/II study to two pivotal phase III trials testing this agent in both chemotherapy-pretreated as well as chemotherapy-naïve CRPC patients. Ongoing studies are aiming to explore the utility of enzalutamide in earlier stages of the disease, and to investigate the optimal sequencing and combination of enzalutamide with other standard and novel therapies for prostate cancer.
Keyphrases
- prostate cancer
- radical prostatectomy
- phase iii
- end stage renal disease
- chronic kidney disease
- clinical trial
- ejection fraction
- squamous cell carcinoma
- locally advanced
- small cell lung cancer
- prognostic factors
- peritoneal dialysis
- single cell
- randomized controlled trial
- double blind
- rectal cancer
- radiation therapy
- middle aged
- case control
- combination therapy
- placebo controlled
- chemotherapy induced